The family of chemical structures that interact with a cannabinoid receptor are broadly
termed cannabinoids. Traditionally known for their psychotropic effects and their use as …

In the last two decades, research has dramatically increased the knowledge of cannabinoids
biology and pharmacology. In mammals, compounds with properties similar to active …

The past decade has witnessed a rapid expansion of our understanding of the biological
roles of cannabinoids and their cognate receptors. It is now certain that Δ9 …

To date, cannabinoids have been allowed in the palliative medicine due to their analgesic
and antiemetic effects, but increasing number of preclinical studies indicates their anticancer …

The endocannabinoid system comprises the G-protein coupled CB1 cannabinoid receptor
(CB1R) and CB2 cannabinoid receptor (CB2R), their endogenous ligands …

Drugs that target the endocannabinoid system are of interest as pharmacological options to
combat cancer and to improve the life quality of cancer patients. From this perspective …

A large body of evidence shows that cannabinoids, in addition to their well-known palliative
effects on some cancer-associated symptoms, can reduce tumour growth in animal models …

Cannabinoids are a class of pharmacologic compounds that offer potential applications as
antitumor drugs, based on the ability of some members of this class to limit inflammation, cell …

The endocannabinoid system (ECS) comprises cannabinoid receptors (CBs), endogenous
cannabinoids, and enzymes responsible for their synthesis, transport, and degradation of …

Endogenous and exogenous cannabinoids modulate many physiological and pathological
processes by binding classical cannabinoid receptors 1 (CB1) or 2 (CB2) or non …